brexucabtagene autoleucel
gilead
['leusm', 'zuma-3', 'leukemia']
congress #eha22 | olalekan o. oluwole from vanderbilt university cancer center presented the results from a subgroup analysis of the zuma-3 trial. adults with r/r b-all benefitted from kte-x19 in all subgroups with a manageable safety profile #allsm #leusm #leukemia 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm